Business Context and Reporting Period
This Form 8-K was filed by BioZone Pharmaceuticals, Inc. (also referred to as BioZone) on October 22, 2013. The report details the termination of a material definitive agreement and the resolution of a dispute regarding a product recall.
Key Financial Metrics
The filing does not provide standard financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The only specific financial figure disclosed is a one-time settlement payment.
- Settlement Payment: $700,000 paid to Zicam, LLC.
- Payment Status: Paid in full within 10 days of the agreement execution.
Material Changes
The primary material change is the termination of the Supply Agreement dated May 8, 2009, between BioZone Laboratories, Inc. and Zicam, LLC. This termination follows a voluntary recall initiated by Matrixx Initiatives, Inc. on December 18, 2012, of a specific lot of Zicam Extreme Congestion Relief nasal gel manufactured by BioZone Labs. Matrixx had previously issued a Notice of Default on January 3, 2013, demanding reimbursement for recall costs.
Outlook, Risks, and Management Commentary
Management resolved the dispute through a Settlement Agreement and Mutual Release. Key outcomes include:
- Release of Obligations: The $700,000 payment settles all remaining amounts due under the Supply Agreement.
- Non-Compete Waiver: Zicam agreed to release BioZone Labs from the post-termination non-compete provision contained in the original Supply Agreement.
- Risk Mitigation: The settlement eliminates the ongoing liability and contractual restrictions associated with the recalled product lot.
Investor Verification Checklist
- Confirm the $700,000 cash outflow has been recorded in the company's most recent financial statements.
- Verify that the termination of the Supply Agreement does not impact other revenue streams or manufacturing contracts.
- Review the company's cash position to ensure the settlement payment did not create immediate liquidity constraints.
- Check for any subsequent litigation or regulatory actions related to the Zicam product recall.